NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Yes Securities Report
Dr. Lal Pathlabs Ltd.'s reported in line growth even as volume growth remains tepid. Management expressed hope about volume recovery on back of initiatives like expansion in tier-III and IV towns, addition of labs and leveraging suburban network.
It is pivoting suburban towards direct to consumer brand though this would be executed over several quarters. Dr. Lal Pathlabs is not looking to take price hike in the near term even as single digit volume growth on a repriced base may make reaching double digit growth a challenging task.
Despite addition of large collection infra over last three years, reckon there is no commensurate volume growth; management is cognisant of volume challenges and hopeful of a rebound, we believe a change to our negative stance is warranted only post revival in volumes.
No major change to our FY24/25 estimate and continue with 'Reduce' rating and unchanged target price Rs 2,500.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Trent Q2 Review - Robust Growth, Albeit Weaker Than Lofty Expectations On Store Consolidation: Motilal Oswal
Nov 08, 2024
Exit Polls And Psephology Can Wait; Maharashtra Growth Is Real, Says Devendra Fadnavis
Oct 27, 2024
Dr. Lal Pathlabs Q2 Results Review - Inline; Volume Growth Still Lackluster: Yes Securities
Oct 24, 2024
KEI Industries Q2 Review - Weak Operating Result A Blip; Robust Outlook Intact: Systematix
Oct 16, 2024
POPULAR